INTRODUCTION {#S5}
============

Mitochondrial diseases due to OxPhos defects and caused by mutations in either the mitochondrial or the nuclear genome are an exceptionally heterogeneous group of disorders. Some are confined to the central or peripheral nervous system (encephalopathy, peripheral neuropathy, and myopathy) but most are multisystemic. Although clinical severity varies, often within families or within cohorts of patients harboring the same pathogenic mutation, by and large these are progressive and often crippling disorders, causing weakness, exercise intolerance, fatigue, ataxia, seizures, mental retardation, dementia, hearing loss, blindness, parkinsonism, strokes, peripheral neuropathies, and premature death. Because of the clinical heterogeneity and the frequent multisystemic involvement, mitochondrial diseases present formidable diagnostic challenges. When accurately diagnosed, they pose even more formidable therapeutic difficulties, as there are very few disease-modifying therapies, and symptomatic therapies, often only anecdotally reported, and are only partially effective.

There is a vibrant international research community engaged in the study of the mechanisms and clinical characterization of mitochondrial diseases and the search for better treatments. However, since there is a large number of distinct mitochondrial diseases, each with relatively low incidence, it has been difficult to assemble sufficiently large datasets or patient groups for research studies and clinical trials.

The North American Mitochondrial Disease Consortium (NAMDC) was established to create a network of clinicians and clinical investigators in North America who follow sizeable numbers of patients with mitochondrial diseases and are interested in mitochondrial research. These "centers of excellence" collaborate with each other and with participating patients to collect vital information and conduct research on mitochondrial diseases. At present, NAMDC is collaborating with some of the leading researchers within the mitochondrial community at 17 academic institutions in United States and Canada \[[Figure 1](#F1){ref-type="fig"}\].

By allowing researchers to aggregate patient data and biological samples from across all member sites, NAMDC eases some of the difficulties associated with studying these rare and diverse diseases. NAMDC is facilitating a number of clinical trials and natural history studies that would otherwise not be feasible due to insufficient sample size.

To join NAMDC, clinical investigators with expertise in mitochondrial diseases are required to submit an official request to the consortium's Principal Investigator and Program Manager explaining how the new site will enhance the ability of the consortium to meet its goals and the commitment to comply will all data standards and study accountability as outlined in the RDRN Policies, Procedures, and Standards. The NAMDC Executive Committee then reviews the request and, if it is approved, forwards it to the Rare Disease Clinical Research Network (RDCRN) Board for final approval. At a minimum, NAMDC sites are required to fully participate in our Registry and Biorepository recruitment; to participate in other consortium activities, including monthly NAMDC and NAMDC Fellowship meetings; and to agree to abide by our research requirements and compliance goals.

METHODS {#S6}
=======

NAMDC registry {#S7}
--------------

To collect information about the wide spectrum of mitochondrial diseases, NAMDC has designed and implemented a comprehensive NAMDC Mitochondrial Disease Clinical Registry that gathers baseline clinical, biochemical, and molecular genetic data and tracks the natural histories of the patients through the NAMDC Clinical Longitudinal study. All data in the NAMDC Registry are handled in a strictly confidential manner. All data are stored in encrypted databases, and all communications of data are password-protected and encrypted. Patient identifiers are stored separately from clinical data and are made available only to authorized users.

Patient enrollment may occur in person at one of the NAMDC member sites or through the Remote Recruitment program streamlined through the NAMDC Clinical Coordinating Center at Columbia University. The web-based remote enrollment ([www.namdc.org](http://www.namdc.org/)) provides a patient-friendly platform that includes passcode access, online screening, electronic consent, and data capture for enrollment of eligible patients who reside far from any of the NAMDC participating sites and/or have difficulties traveling to the sites due to their disabilities.

The NAMDC Clinical Registry is also the base for developing the NAMDC Clinical Registry/Longitudinal Study to collect natural history data across the spectrum of mitochondrial diseases.

NAMDC research diagnostic criteria {#S8}
----------------------------------

Because of the vast clinical and genetic heterogeneity of mitochondrial diseases, diagnosing these disorders is challenging, but critical to assess the natural histories, define prognoses, study pathogenic mechanisms, and develop clinical trials. To facilitate accuracy and uniformity of the diagnosis of mitochondrial disease, NAMDC investigators in various disciplines including Neurology, Internal Medicine, Pediatrics, Pathology, Clinical Genetics, Clinical Laboratory Medicine, and Biostatistics, have generated NAMDC Research Diagnostic Criteria for mitochondrial diseases with strict benchmarks for definite, suspected, or unlikely levels of diagnoses. Data derived from the registry have been the source for the development and refinement of the diagnostic criteria, which are being applied on a research basis to classify patients in the NAMDC Registry. The NAMDC research diagnostic criteria are outlined in a separate report that is currently in preparation for publication.

NAMDC biorepository {#S9}
-------------------

At the time of consent into the NAMDC Patient Registry, patients are provided with the opportunity to submit samples to the NAMDC Biorepository. Samples of blood, urine, and other tissues are then collected and deposited into the NAMDC Biorepository. The NAMDC Biorepository is located at the Mayo Clinic Biospecimens Accessioning and Processing (BAP) Core in Rochester, Minnesota. Participation in the Biorepository is optional.

The NAMDC Clinical Registry, Research Diagnostic Criteria, and Biorepository are three pillars that form a strong foundation for multi-center collaborative mitochondrial disease research. The NAMDC registry includes a data-mining tool to facilitate access to de-identified data among NAMDC investigators as well as a consortium-style Master Service Agreement that allows transfer of de-identified biosamples among NAMDC sites, and to other external entities upon the appropriate approval.

NAMDC pilot program {#S10}
-------------------

The Pilot Project Program is an important component of NAMDC, and supports 1--2 pilot projects annually. NAMDC pilot projects focus on biomarkers, diagnosis, natural history, and treatment of mitochondrial diseases. Thus, projects must be human subject studies, i.e., include patients, human cells, tissues, or body fluid samples. Pilot grants are often a first step for junior investigators, for whom the grant application is frequently the first formal funding application. The Pilot Core provides multiple mentoring steps for junior investigators including feedback on initial proposals (including unfunded proposals to improve the quality of the application), throughout the grant development process, and during project implementation. Mentoring is done by the NAMDC PI, Statistical PI, Pilot Core PI, local site PI, NAMDC Clinical Liaison, and additional collaborators as needed.

The NAMDC Pilot Program Committee is responsible for reviewing the pilot/new project proposals. Applicants for Pilot Projects must be NAMDC members. The NAMDC Pilot Project Committee recommends funding decisions that best meet the needs and priorities of the consortium and encourage its growth. Selection for funding is based upon information from written peer review and from the NAMDC PIs following oral presentation at the annual Face-to-Face meeting. Following the recommendation by the Pilot Program Committee, the NAMDC Executive Committee makes the ultimate decision as to what pilot/new projects are funded with input from the RDCRN and approval from the NIH officers. Multicenter studies are prioritized over single-site study projects. Applicants apply for funding for projects that occur during the 12-month window of the NAMDC yearly cycle of NIH funding. This means that applicants apply for projects that will be carried out from 1 September to 31 August of the following year. Grantees are expected to submit a brief quarterly report, a preliminary report presentation at the annual Face-to-Face meeting, and a final report within two months of the conclusion of the grant.

The NAMDC career enhancement program {#S11}
------------------------------------

There is a severe shortage of physicians trained to diagnose and treat pediatric and adult patients with mitochondrial disease. The NAMDC Career Enhancement Program is designed to provide training in rare disease with a focus on mitochondrial medicine. The program consists of the following components:

The NAMDC Fellowship Program, which offers a unique training opportunity to senior postdoctoral clinical fellows to move on to the attending/assistant professor level in an academic setting as well-trained clinician scientists. The focus is on translational medicine, teaching of diagnostic expertise, and the development of clinical trials expertise. NAMDC aims to train the first of a new generation of clinician scientists who will be well equipped to move promising new treatments for mitochondrial disease into the clinical arena. Nine training sites are collaborating in this program. These sites - Columbia, San Diego, Seattle, Cleveland, Hamilton, CHOP, Baylor, University of Colorado, and Mayo Clinic - are all leading institutions in the field of mitochondrial medicine. World-renowned faculty are to be found at each site. Fellows participate in RDCRN training courses where they present a summary of their work.

The fellowship program is unified by telemedicine conferences led by the NAMDC Career Enhancement PI and involves all consortium sites with monthly video webinar conferencing. These conferences are well attended by faculty, students, and NIH representatives. RDCRN trainees are also invited to participate.

A Career Enhancement program is being developed to include: (1) a didactic core lecture series on Clinical Trial readiness to be available as an online lecture series; (2) the directors of the 10 Career Enhancement Sites to post a comprehensive series of lectures on management of mitochondrial disease; and (3) the Mitochondrial Medicine Society to develop a series of organ-specific mitochondrial disease lectures to be CME-certified by the United Mitochondrial Disease Foundation (UMDF) and made available online.

Funds provided by the UMDF will be used to attract young physicians, medical students, MD/PhD students, and recent graduates heading to medical school and the field of mitochondrial medicine. A committee of Site Directors and UMDF grant reviewers will review proposals. In addition, an annual retreat will take place on the day following the UMDF annual meeting where the awardees and the NAMDC fellow can interact with and present their work to the Site Directors.

NAMDC administrative core {#S12}
-------------------------

The Administrative Core of NAMDC provides critical organizational and strategic support to assure the overall success of the Program in accordance with NIH RDCRN program objectives. As the central hub and coordinating center for all NAMDC projects, the Administrative Core manages the interactions between multiple academic departments and between the Consortium and external organizations and institutions. The Core has an Overall Program Director/Principal Investigator, a Statistical Principal Investigator, a Clinical Team Liaison, a Bioinformatician, and an Administrative Coordinator, with ultimate responsibility for the Program's scientific, clinical research, and training/educational operations. The NAMDC Executive Committee (EC) consists of these individuals plus the Chairs of the seven NAMDC Standing Committees (Data Use Committee, Biorepository Committee, Career Enhancement Program Committee, Pilot/New Project Program Committee, Publications Committee, Website Committee, and Diagnostic Committee), two NIH Representatives, and one Patient Advocacy Group representative. The EC meets regularly to assess the progress of NAMDC programs (protocols, initiatives, *etc.*), set the long-term strategic goals for the Consortium, and define the terms and rules by which the Consortium interacts with outside entities (Patient Advocacy Groups, non-NAMDC researchers, industry, *etc.*).

The Administrative Core also maintains three independent websites: (1) an internal website to manage internal documents and communications with NAMDC sites; (2) a patient remote enrollment website ([www.namdc.org](http://www.namdc.org/)) recently expanded for remote enrollment in Latin America ([www.namdc.org/sp](http://www.namdc.org/sp)); and (3) an external website coordinated with RDCRN to publicly communicate NAMDC's mission and the availability of training opportunities and core services (<https://www.rarediseasesnetwork.org/cms/namdc/>).

RESULTS {#S13}
=======

NAMDC clinical registry and biorepository {#S14}
-----------------------------------------

NAMDC is part of the Rare Diseases Clinical Research Network (RDCRN) funded by the National Institute of Health (NIH U54NS078059). NAMDC has established a network of 17 clinical centers of excellence to improve the diagnosis, natural history, and treatment of mitochondrial diseases \[[Figure 1](#F1){ref-type="fig"}\]. NAMDC sites' enrollment of mitochondrial disease patients is progressing steadily with more than 1600 patients enrolled to date \[[Figure 2](#F2){ref-type="fig"}\]. The proportion of female participants in the registry population is 14.6% higher than male population and there is a notable under-representation of certain patient groups - individuals over age 65 year comprise only 3% and African American subjects represent only 2.4% (see [Supplementary Materials](#SD1){ref-type="supplementary-material"}). To enhance recruitment, the NAMDC Central Coordinating Center has also implemented a remote patient recruitment system which has been successfully enrolling domestic and international patients since 2018. Data from the NAMDC Clinical Registry \[[Table 1](#T1){ref-type="table"}\] have been analyzed, and and published in the journal of Neurology Genetics (Barca *et al*.^\[[@R1]\]^ 2020). A data-mining tool has been programmed to allow NAMDC site investigators to perform data queries for internal use. NAMDC is expanding the Registry to collect natural history data on all enrolled patients with select diseases. Additionally, the NAMDC Biorepository currently holds more than 330 biological samples as well as a virtual fibroblast of 185 cell lines. A Central IRB at Columbia University Medical Center has been established for this program.

NAMDC pilot program {#S15}
-------------------

To date, nine pilot projects have been awarded. Some of them have been completed and published^\[[@R1]--[@R4]\]^, and others are in progress. The awarded projects focus on development of biomarkers, improving diagnostic tools, characterizing natural history, and testing therapies for mitochondrial diseases \[[Table 2](#T2){ref-type="table"}\].

The NAMDC career enhancement program {#S16}
------------------------------------

The NAMDC Fellowship program has been highly successful with monthly webinar meetings and didactic training of six fellows. The first three trainees who completed the program have obtained faculty positions and are active mitochondrial disease clinician investigators. The three latest trainees are continuing their clinical training within the field of neurogenetics.

NAMDC survey studies {#S17}
--------------------

In addition to the pilot studies, five patient surveys have been assessed through the NAMDC Registry: (1) attitudes of women carrying mitochondrial DNA mutations and healthy egg donors regarding oocyte nuclear transfer to prevent transmission of mtDNA disease; (2) nutritional supplement use in mitochondrial disease; (3) cardiovascular events in patients with metabolic diseases on chronic carnitine supplementation; (4) motivations and barriers for participation in clinical trials by individuals with mitochondrial diseases; and (5) the diagnostic odyssey of mitochondrial disease patients. Results of four of the five completed surveys have been published^\[[@R5]--[@R8]\]^. In addition, a survey of NAMDC investigators regarding the NAMDC Research Diagnostic Criteria has been completed and the results have contributed to the refinement of the NAMDC Diagnostic Criteria.

DISCUSSION {#S18}
==========

Mitochondrial diseases are challenging because they may be the most diverse human disorders at every level: clinical, biochemical, and genetic. Some are confined to the nervous system but most are multi-systemic, often affecting the brain, heart, liver, skeletal muscle, kidney, endocrine, and respiratory systems. Although severity varies, largely these are progressive and often crippling disorders. They frequently cause weakness, exercise intolerance, fatigue, seizures, mental retardation, dementia, hearing loss, blindness, and premature death.

The challenge lies in the extraordinary clinical spectrum of mitochondrial diseases, which all too often leads practitioners to either underdiagnose ("what is this complex disorder?") or to overdiagnose ("this disorder is so complex that it must be mitochondrial!"). The diagnostic difficulty is reflected in the diagnostic odyssey encountered by patients; in our survey study utilizing the RDCRN Contact Registry, subjects reported seeing, on average, more than eight clinicians before being given the diagnosis of mitochondrial disease^\[[@R4]\]^. Given this heterogeneity of mitochondrial disorders, it is essential to apply common, agreed-upon standards to the diagnosis and classification of patients. Further, given the variety of clinical and biochemical phenotypes, effective research on any given subset depends on aggregating relatively large numbers of patients.

These exigencies make clear that two prerequisites are necessary before effective clinical research can take place: (1) a clinical patient registry/longitudinal study to evaluate and expedite subsequent research with available patients; and (2) uniform diagnostic criteria for mitochondrial diseases. NAMDC was established with the goal of addressing these essential elements. After 8 years of continuous support of a U54 RDCRN cooperative agreement, NAMDC has built a basic infrastructure, established a robust clinical registry, expanded the NAMDC Biorepository, plans to implement a registry-wide Natural History study for more common mitochondrial disorders, continues support of pilot projects, and plans to expand the career enhancement program to train new mitochondrial disease investigators. Furthermore, NAMDC plans to collaborate in the international data-harmonization efforts aiming to provide users with access to a comparable view of data from global mitochondrial registries. As NIH funding of projects has a finite lifespan, NAMDC leadership is implementing innovative and cost-effective alternatives such as remote enrollment and is assembling a patchwork of funding sources by ensuring industrial support and strategic collaboration with the UMDF non-for-profit enterprise. Through this approach, NAMDC aims to build a critical infrastructure and performance level to support a resource-efficient and sustainable plan for future mitochondrial disease research in North America and in collaboration with international partners.
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======================
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###### 

Frequency of the various mitochondrial clinical syndromes among enrolled participants as of December 31, 2019

  Clinical syndromes                                                   Totals   Percent (%)
  -------------------------------------------------------------------- -------- -------------
  Alpers syndrome                                                      23       1.5
  Cardiomyopathy                                                       12       0.8
  CPEO                                                                 56       3.7
  CPEO "plus"                                                          60       3.9
  Diabetes and deafness                                                24       1.6
  Kearns-Sayre syndrome                                                39       2.6
  LHON                                                                 42       2.8
  Leigh syndrome                                                       189      12.4
  Maternal-inherited deafness                                          9        0.6
  MELAS                                                                109      7.1
  MNGIE                                                                18       1.2
  Multi-systemic syndrome                                              290      19.0
  MERRF                                                                24       1.6
  Myopathy                                                             81       5.3
  NARP                                                                 17       1.1
  Pearson syndrome                                                     21       1.4
  Reversible infantile myopathy with cytochrome c oxidase deficiency   3        0.2
  SANDO                                                                24       1.6
  Barth syndrome                                                       3        0.2
  Encephalomyopathy                                                    95       6.2
  Hepatocerebral syndrome                                              8        0.5
  Leukoencephalopathy                                                  9        0.6
  Encephalopathy                                                       77       5.0
  Other clinical syndrome/symptoms                                     296      19.4

cPEO: chronic progressive external ophthalmoplegia; SANDO: sensory ataxic neuropathy with dysarthria and ophthalmoparesis; NARP: neuropathy, ataxia, and retinitis pigmentosa; MERRF: myoclonus epilepsy with ragged red fibers; MNGIE: mitochon-drial neurogastrointestinal encephalopathy; MELAS: mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; LHON: Leber hereditary optic neuropathy

###### 

NAMDC-funded pilot projects

  RDCRN protocol number   Pilot project title                                                                                                                                                               Project principal investigator/site
  ----------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------
  NAMDC7407               Prototype development of an exome variant analysis pipeline and public interface for the community-wide Mitochondrial Disease Sequence Data Resource (MSeqDR)^\[[@R2]--[@R4]\]^   Marni Falk, MD, Children's Hospital of Philadelphia
  NAMDC7408               Natural history of pearson syndrome                                                                                                                                               Sumit Parikh, MD, Cleveland Clinic
  NAMDC7416               Citrulline supplementation for treatment of nitric oxide deficiency in MELAS: a Phase 1 dose-finding and safety study                                                             Fernando Scaglia, MD, Baylor College of Medicine
  NAMDC7415               The clinical utility and a clinician's guide to new mitochondrial functional tests^\[[@R1]\]^                                                                                     JohanL. K. Van Hove, MD, PhD
  NAMDC7417               Activators of AMPK for Treatment of Mitochondrial Disorders                                                                                                                       Tina M. Cowan, PhD, Stanford University
  NAMDC7418               Genomic testing for molecularly undefined NAMDC Registry cases                                                                                                                    Amel Karaa, MD, Massachusetts General Hospital
  NAMDC7420               The use of amino acids to enhance the activity of enzymes involved in mitochondrial translation defects: a possible therapeutic approach                                          Marisa Friederich, PhD, University of Colorado
  NAMDC7421               Development of Minimally Invasive Nanosensor Technology to Quantify Mitochondrial Function in Human Muscle                                                                        Zarazuela Zolkipli Cunningham, MBChB MRCP, Children's Hospital of Philadelphia

NAMDC: North American Mitochondrial Disease Consortium; RDCRN: Rare Diseases Clinical Research Network; AMPK: adenosine monophosphate--activated protein kinase; MELAS: mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes
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